Nyxoah Launches Genio® Therapy in Middle East

Nyxoah SA, a Belgian medical technology firm, has announced the commercial launch of its Genio® system in the Middle East. The Genio system, which offers a novel treatment for Obstructive Sleep Apnea (OSA) through neuromodulation, was successfully implanted in its first patient at Saudi German Hospital in Dubai.

This milestone marks the introduction of the first neurostimulation therapy for OSA in the region. The procedure was performed by Dr. Ahmed Yassin Bahgat, who expressed pride in providing this innovative treatment to patients intolerant to CPAP therapy. Nyxoah's CEO, Olivier Taelman, emphasized the company's commitment to expanding Genio's reach and transforming OSA treatment globally.

Nyxoah's Genio system has European CE Mark approval and is pending FDA approval in the United States. The company aims to enhance patient outcomes and broaden access to effective OSA treatment worldwide.